Study Payments Clause Samples

The Study Payments clause defines the terms and conditions under which payments are made for conducting a study, typically in the context of clinical trials or research agreements. It outlines the schedule, method, and criteria for payment, such as milestone achievements, submission of data, or completion of specific study activities. This clause ensures that both parties understand when and how funds will be disbursed, thereby providing financial clarity and reducing the risk of disputes over payment obligations during the course of the study.
Study Payments. The payment for completing the entire study is listed below. Please be aware that:  If you do not follow instructions (including those listed in the New Haven CRU House Rules), if you are late for blood draws, or if you miss procedures, your payment may be reduced. You will be paid a prorated amount based on the extent of your participation if: o You are not able to complete the study o You choose to leave the study o You are withdrawn from the study early by the study investigator for non-safety-related issues o The study is stopped early o You are qualified but not chosen to participate  You will not be given the study completion bonus if you drop out of the study early  Partial payments are planned during the study. Details will be provided at screening  A final payment will be provided to you within 2 weeks of finishing the study  If total payment by Pfizer is $600.00 or more in a calendar year, your payment will be reported to the Internal Revenue Service in accordance with Federal tax law; in some countries compensation may not be allowed due to immigration status  Pfizer may use information resulting from the study or samples collected in the study to develop products or processes. Pfizer may make a profit from these. There are no plans to pay you or provide you with any products developed from this research. Pfizer will own all products or processes that are developed using information or samples from the study  You may be offered transportation to and from the study site and lodging at no additional charge to you The decision to admit you into the study is based upon results of pre-study requirements. No one is guaranteed a place in the study until the first dose is complete. Enough numbers of participants will be brought in to be sure we fill the study. Overnight Stay* $225.00 12 Washout Period Between Doses $100.00 0 Follow-Up Visit to CRU $250.00 0 planned Time Between Discharge and Follow-Up Phone Call $100.00 4 weeks Completion Bonus $900.00 Total Payment $4,000.00 Overnight Stay* $300.00 Daytime Stay $190.00 *Overnight stay rates include an increase for COVID restriction inconveniences Additional payments are made if we ask you to return to the CRU or to outside medical providers for additional tests ($250.00 per visit). During times that you need to stay in the CRU, you will not be paid more for repeat or added tests.
View SourceView Similar (21)
Study Payments. The payment for completing the entire study is listed below. Please be aware that: • If you do not follow instructions (including those listed in the New Haven CRU House Rules), if you are late for blood draws, or if you miss procedures, your payment may be reduced. You will be paid a prorated amount based on the extent of your participation if: o You are not able to complete the study o You choose to leave the study o You are withdrawn from the study early by the study investigator for non-safety-related issues o The study is stopped early o You are qualified but not chosen to participate • You will not be given the study completion bonus if you drop out of the study early • Partial payments are planned during the study. Details will be provided at screening • A final payment will be provided to you within 2 weeks of finishing the study • Pfizer may use information resulting from the study or samples collected in the study to develop products or processes. Pfizer may make a profit from these. There are no plans to pay you or provide you with any products developed from this research. Pfizer will own all products or processes that are developed using information or samples from the study The decision to admit you into the study is based upon results of pre-study requirements. No one is guaranteed a place in the study until the first dose is complete. Enough numbers of participants will be brought in to be sure we fill the study.
View SourceView Similar (3)
Study Payments. Clauses 2.1 to 2.7 explain the payments you will receive under this Agreement. 2.1 There are two parts to your Scholarship: Fees and Allowances. 2.2 Your Fees will be paid directly to your Tertiary Provider from the year you are awarded your Scholarship to cover the minimum EFTS required to complete the teaching qualification, while you have Fees entitlement remaining. 2.3 You will be paid an Allowance of up to $30,000 per year after your Fees have been paid only if: • You are an approved full-time student or a limited full-time student; • you have allowance entitlement remaining; and • you pass 100% of your Study during the previous Academic Study Year (for the second and following years of your Study); • you resit a failed paper or pass a teaching paper of equivalent EFTS value at your own expense in the same Academic Study Year. 2.4 The Allowance will be paid in Fortnightly Instalments directly into your bank account for a maximum period of one to three years. 2.5 If you are starting your studies Mid-Year the payments will be split to match your academic year of Study. 2.6 If you receive an Allowance overpayment that you were not eligible to receive, you must repay the amount to StudyLink within 28 days of receiving advice regarding the overpayment. 2.7 If the amount is not repaid, the amount of the overpayment will be deducted from your remaining allowance entitlement.
View SourceView Similar (2)
Study Payments. The payment for completing the entire study is listed below. Overnight Stay $400.00 18 $7,200.00 Follow Up Phone Call $100.00 1 $100.00 Completion Bonus $900.00 $900.00 Total Payment $8,200.00 • Partial payments are planned during the study. Details will be provided at screening • A final payment will be provided to you within 2 weeks of finishing the study • Additional payments are made if we ask you to return to the CRU or to outside medical providers for additional tests ($150.00 per visit). During times that you need to stay in the CRU, you will not be paid more for repeat or added tests • You will be eligible for the completion bonus after all study visits have been completed, including follow up visits, follow up phone call, and any unplanned study visits requested by the study investigator • Pfizer may use information and biological samples resulting from the study to develop products or processes from which it may profit. There are no plans to pay you or provide you with any products developed from this research. Pfizer will own all products or processes that are developed using information or samples from the study You may be eligible for a travel and hotel bonus payment for costs incurred traveling to study visits: • $0.20/mile per one-way trip to or from the CRU based on your home address up to a maximum of $300 per one-way trip • For participants traveling long distances, a 1-night hotel stipend ($150.00) for the night prior to your visit(s), if needed
View Source
Study Payments. The payment for completing the entire study is listed below. Please be aware that: • If you do not follow instructions (including those listed in the New Haven CRU House Rules), if you are late for blood draws, or if you miss procedures, your payment may be reduced. You will be paid a prorated amount based on the extent of your participation if: o You are not able to complete the study o You choose to leave the study o You are withdrawn from the study early by the study investigator for non-safety-related issues o The study is stopped early o You are qualified but not chosen to participate • You will not be given the study completion bonus if you drop out of the study early • Partial payments are planned during the study. Details will be provided at screening • A final payment will be provided to you within 2 weeks of finishing the study • Pfizer may use information resulting from the study or samples collected in the study to develop products or processes. Pfizer may make a profit from these. There are no plans to pay you or provide you with any products developed from this research. Pfizer will own all products or processes that are developed using information or samples from the study The decision to admit you into the study is based upon results of pre-study requirements. No one is guaranteed a place in the study until the first dose is complete. Enough numbers of participants will be brought in to be sure we fill the study. Overnight Stay $215.00 3 $645.00 Duration of Follow-Up Period (Discharge to Follow-up Call) $15.00 28 $420.00 Follow-Up Phone Call $100.00 1 $100.00 Completion Bonus $300.00 $300.00 Total Payment $1,465.00 Overnight Stay $300.00 Daytime Stay $190.00 Additional payments are made if we ask you to return to the CRU or to outside medical providers for additional tests ($250.00 per visit). During times that you need to stay in the CRU, you will not be paid more for repeat or added tests.
View Source

Related to Study Payments

  • EXPENSE PAYMENTS The Owner hereby gives power to the Agent to pay expenses and costs for the Property from the Owner’s funds held by the Agent, unless otherwise directed by the Owner. The expenses and costs may include, but are not limited to, property management compensation, fees and charges, expenses for goods and services, property taxes and other taxes, association or condominium dues, assessments, loan payments, and insurance premiums.

  • Royalty Payments 6.1 During the TERM of this Agreement, as partial consideration for the LICENSE, LICENSEE shall pay to YALE an earned royalty of [***] percent ([***]%) of worldwide cumulative NET SALES of LICENSED PRODUCTS by LICENSEE or its SUBLICENSEES or AFFILIATES (“EARNED ROYALTY”). 6.1.1 The obligation to pay royalties under this Article 6.1 shall be imposed only on the original sale of any individual LICENSED PRODUCT to the end-user thereof, and the royalty shall be imposed only once on such sale regardless of whether such LICENSED PRODUCT is covered by more than one patent claim within the LICENSED PATENTS. 6.1.2 In the event that LICENSEE determines that it is necessary to obtain a license from a third party in order to avoid infringing a third party’s patent(s) by making, having made, using, offering for sale, selling, having sold, importing or exporting LICENSED PRODUCTS, LICENSEE may reduce its applicable royalty obligation to YALE by an amount which is the lesser of (i) [***], or (ii) [***]. 6.1.3 The multiplier to be used to reduce the running royalties paid by LICENSEE to YALE on a COMBINATION PRODUCT, defined as a product containing a LICENSED PRODUCT and one or more additional products containing active ingredients sold together as a single product by LICENSEE, AFFILIATES or SUBLICENSEES, will be calculated by [***]. 6.1.4 Notwithstanding the foregoing, in no event shall the operation of Articles 6.1.2 or 6.1.3 result in EARNED ROYALTIES payable to YALE being reduced to less than [***] percent ([***]%). 6.1.5 Should a compulsory license be granted by LICENSEE or an AFFILIATE to a third party under the applicable laws, rules, regulations, guidelines, or other directives of any governmental or supranational agency in the LICENSED TERRITORY under the LICENSED PATENTS, LICENSEE shall notify YALE, including any material information concerning such compulsory license, and the running royalty rates payable under Article 6.1 for sales of LICENSED PRODUCTS in such country will be adjusted to equal any lower royalty rate granted to such third party for such country with respect to the sales of LICENSED PRODUCTS therein. 6.2 In the event that (i) LICENSEE or any of its AFFILIATES or SUBLICENSEES brings a PATENT CHALLENGE anywhere in the world, or (ii) LICENSEE or any of its AFFILIATES or SUBLICENSEES assists another party in bringing a PATENT CHALLENGE anywhere in the world, and (iii) YALE does not choose to exercise its rights to terminate this Agreement pursuant to Article 13, then the following provisions shall apply. (a) All payments due to YALE under this Agreement other than patent costs shall be [***] during the pendency of the PATENT CHALLENGE and shall remain payable to YALE when due. (b) If the PATENT CHALLENGE is inconclusive or results in a determination that at least one challenged claim is both valid and infringed, (i) all payments due to YALE under this Agreement other than patent costs shall be [***] for the remainder of the TERM of the Agreement. (ii) LICENSEE shall promptly reimburse YALE for all legal fees and expenses incurred in YALE’s defense against the PATENT CHALLENGE. (c) In the event that such a PATENT CHALLENGE is successful, LICENSEE will have no right to recoup any payments made prior to the final, non-appealable determination of a court of competent jurisdiction. 6.3 Neither LICENSEE nor any of its AFFILIATES or SUBLICENSEES shall bring a PATENT CHALLENGE without first providing YALE [***] written notice setting forth (a) precisely which claims and patents are being challenged or claimed not to be infringed, (b) a clear statement of the factual and legal basis for the challenge, and (c) an identification of all prior art and other matter believed to invalidate any claim of the LICENSED PATENT or which supports the claim that the LICENSED PATENT is not infringed. 6.4 LICENSEE shall pay all EARNED ROYALTIES accruing to YALE within [***] from the end of each calendar quarter (March 31, June 30, September 30 and December 31), beginning in the first calendar quarter in which NET SALES occur. Unless YALE requests otherwise, LICENSEE shall report all EARNED ROYALTIES and other payments accruing to YALE on a quarterly basis, but shall defer payments accruing to YALE that do not, in total, exceed [***] Dollars ($[***]) in any given quarter until the earlier of (1) the end of the calendar year, or (2) the quarter upon which the cumulative accrued royalties and other payments exceed [***] Dollars ($[***]). 6.5 All EARNED ROYALTIES and other payments due under this Agreement shall be paid to YALE in United States Dollars. In the event that conversion from foreign currency is required in calculating a payment under this Agreement, the exchange rate used shall be the Interbank rate quoted by Citibank at the time the payment is due. If overdue, the royalties and any other payments due under this Agreement shall bear interest until payment at a per annum rate [***] percent ([***]%) above the prime rate in effect at Citibank on the due date. The payment of such interest shall not foreclose YALE from exercising any other right it may have as a consequence of the failure of LICENSEE to make any payment when due.

  • FILOT PAYMENTS Section 4.01

  • Longevity Payments (a) Longevity payments as set out in the salary schedule in Appendix A-1 (Interest Arbitration ineligible employees) and Appendix A-2 (Interest Arbitration eligible employees) will be provided to eligible employees upon completion of 10, 15, 20 and 25 years of continuous service. Continuous service shall mean time in a title or combination of titles which have existed and/or presently exist in the Security Services Unit, Agency Police Services Unit or Security Supervisors Unit. Such payment will be added to base pay effective on the payroll period which next begins following the actual completion of 10, 15, 20 and 25 years of continuous service. (b) In no event may an employee's basic annual salary exceed the longevity maximum of the salary grade as the result of the longevity payment or adjustment. (c) Employees whose basic annual salary after the application of the general increase and implementation of the new salary schedule is above the job rate will be considered to have received longevity payments in the amount by which their basic annual salary exceeds the job rate for their grade. (d) Such longevity payments will be added to and considered part of base pay for all purposes except for determining an employee's change in salary upon movement to a different salary grade and his potential for movement to the job rate of the new grade, after which determination the appropriate longevity payments will be restored. (e) The longevity amount for all employees will be adjusted to reflect the longevity payments which are appropriate to their current salary grade.

  • Reimbursement Payments The Department shall, to the extent funds are available, reimburse the Grantee for eligible claims presented for payment if the Department determines the requirements for reimbursement have been met. Claims under this Contract can only be made for the period this Contract is in effect. Reimbursement programs include the following: 4.3.1. Title IV-E Federal ▇▇▇▇▇▇ Care Program (Grant “E”). In accordance with the requirements detailed in the specific grant requirements, the Department shall reimburse the Grantee under ▇▇▇▇▇ E the maximum federal dollar share for the following: ▇▇▇▇▇▇ care maintenance claims for eligible juvenile probation children, dir ect administrative claims, and enhanced administrative claims. Upon review and approval of supporting documentation, the Department shall reimburse the Grantee as requests for reimbursement are presented for payment provided there is sufficient Title IV-E grant award authority against which to process presented claims and providing said funds are being reimbursed to the Department by Texas Department of Family and Protective Services (TDFPS) via the interagency agreement. To be eligible for reimbursement, all costs must be reasonable, allowable, and properly allocated for support of the ▇▇▇▇▇▇ care program. A direct or enhanced administrative claim is not eligible for reimbursement if the basis of the claim has funding from any other federal source. 4.3.2. JJAEP Program (Grant "P"). Grantees eligible for reimbursements under ▇▇▇▇▇ ▇ shall receive a share of the initial $1,500,000 distribution based on each Grantee's share of the total juvenile population for each school year for the current contract period. Additional funds will be distributed at a rate not to exceed $96 per eligible student attendance day for students who are required to be expelled pursuant to Chapter 37 of the Texas Education Code and who meet the Targeted Grant requirements. The Grantee will not be able to receive the additional funds until the initial amount allocated is earned at the rate of $86 per eligible student attendance day. Payments to the Grantee by the Department shall be limited to no more than 180 days of operation during each regular school year for the current contract period.